title: Peginesatide acetate, axitinib, and pertuzumab.
authors.affiliation: Philadelphia College of Pharmacy, University of the Sciences in Philadelphia, PA, USA.
authors.forename: Daniel A
authors.initials: DA
authors.lastname: Hussar
authors.forename: Andrew T
authors.initials: AT
authors.lastname: Genco
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000077784:Axitinib; D001943:Breast Neoplasms / Q000188:drug therapy; D002292:Carcinoma, Renal Cell / Q000188:drug therapy; D002986:Clinical Trials as Topic; D017277:Drug Approval; D005260:Female; D006397:Hematinics / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D007191:Indazoles / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D010455:Peptides / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D051436:Renal Insufficiency, Chronic / Q000188:drug therapy
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D006397:Hematinics; D007093:Imidazoles; D007191:Indazoles; D010455:Peptides; D000077784:Axitinib; C556270:peginesatide; C485206:pertuzumab